Celecoxib
FDA-approved product (capsule, oral), marketed as Celebrex, Celecoxib, Elyxyb and 1 more.
- Registered studies
- 50+
- Lab records
- 1
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Ankylosing spondylitis
- Cancer
- Colorectal neoplasm
- Dysmenorrhea
- Familial adenomatous polyposis
- Familial adenomatous polyposis 1
- Hemorrhage
- Juvenile idiopathic arthritis
- Migraine disorder
- Neoplasm
- Osteoarthritis
- Pain
- Peptic ulcer
- Peptic ulcer disease
- Rheumatic disease
- Rheumatoid arthritis
- and 2 more
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents; Coxibs
- FDA pharmacologic class
- Nonsteroidal Anti-inflammatory Drug FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis87.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- M. tuberculosis: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Celecoxib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain
NCT01062113 · start 2010-04
Registered record
- Registry ID
- NCT01062113
- Conditions
- Pain
- Interventions
- Celecoxib; Celecoxib; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2010-08
- Enrolment
- 255
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionCelecoxib; Celecoxib; PlaceboPhasePhase 2Registry statusCompletedStudy of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise
NCT01020279 · start 2009-10
Registered record
- Registry ID
- NCT01020279
- Conditions
- Musculoskeletal Pain
- Interventions
- Celecoxib, Ketoprofen; Ketoprofen
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-10
- Completion
- 2010-01
- Enrolment
- 82
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMusculoskeletal PainInterventionCelecoxib, Ketoprofen; KetoprofenPhasePhase 1Registry statusCompletedProtocol for the Treatment of Metastatic Ewing Sarcoma
NCT02727387 · start 2009-06-01
Registered record
- Registry ID
- NCT02727387
- Conditions
- Ewing's Sarcoma (ES)
- Interventions
- TEMIRI; ADM; IFO; CYC; ETO; BUMEL; VIN
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-06-01
- Completion
- 2022-04-29
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEwing's Sarcoma (ES)InterventionTEMIRI; ADM; IFO; CYC +3 morePhasePhase 2Registry statusCompletedEfficacy and Safety of Shinbaro Capsule
NCT01535417 · start 2009-05
Registered record
- Registry ID
- NCT01535417
- Conditions
- Osteoarthritis
- Interventions
- Shinbaro Capsule; Celebrex
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-05
- Completion
- 2009-12
- Enrolment
- 198
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritisInterventionShinbaro Capsule; CelebrexPhasePhase 3Registry statusCompletedNaturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
NCT00688545 · start 2009-04
Registered record
- Registry ID
- NCT00688545
- Conditions
- Arthritis, Juvenile Rheumatoid
- Interventions
- Celecoxib; nsNSAIDs
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2009-04
- Completion
- 2012-01
- Enrolment
- 275
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArthritis, Juvenile RheumatoidInterventionCelecoxib; nsNSAIDsPhaseNot recordedRegistry statusTerminatedA Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
NCT00813241 · start 2009-01
Registered record
- Registry ID
- NCT00813241
- Conditions
- Healthy Volunteers
- Interventions
- celecoxib reference formulation; celecoxib test formulation A1; celecoxib test formulation B2; celecoxib test formulation C1
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2009-03
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventioncelecoxib reference formulation; celecoxib test formulation A1; celecoxib test formulation B2; celecoxib test formulation C1PhasePhase 1Registry statusCompletedChanges in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
NCT01425476 · start 2008-07
Registered record
- Registry ID
- NCT01425476
- Conditions
- Breast Cancer
- Interventions
- Celecoxib; Placebo; Cholecalciferol
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2016-11
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionCelecoxib; Placebo; CholecalciferolPhasePhase 1 / Phase 2Registry statusCompletedCelebrex In Acute Gouty Arthritis Study
NCT00549549 · start 2008-02
Registered record
- Registry ID
- NCT00549549
- Conditions
- Arthritis, Gouty
- Interventions
- Indomethacin; Celecoxib; Celecoxib; Celecoxib
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2009-12
- Enrolment
- 402
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArthritis, GoutyInterventionIndomethacin; Celecoxib; Celecoxib; CelecoxibPhasePhase 3Registry statusCompletedThe Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
NCT00624559 · start 2008-02
Registered record
- Registry ID
- NCT00624559
- Conditions
- Hypertension
- Interventions
- celecoxib (Celebrex); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2009-01
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventioncelecoxib (Celebrex); PlaceboPhasePhase 4Registry statusCompletedA Study of High-Risk Oral Cavity Cancer
NCT00934739 · start 2007-06
Registered record
- Registry ID
- NCT00934739
- Conditions
- Oral Cavity Cancer
- Interventions
- Thalidomide, Celebrex; Cyclophosphamide, Dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Terminated
- Start
- 2007-06
- Completion
- 2012-12
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOral Cavity CancerInterventionThalidomide, Celebrex; Cyclophosphamide, DexamethasonePhasePhase 2 / Phase 3Registry statusTerminatedProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
NCT00346216 · start 2006-10-04
Registered record
- Registry ID
- NCT00346216
- Conditions
- Arthritis, Rheumatoid
- Interventions
- celecoxib; Ibuprofen; Naproxen
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-10-04
- Completion
- 2016-04-12
- Enrolment
- 24,081
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArthritis, RheumatoidInterventioncelecoxib; Ibuprofen; NaproxenPhasePhase 4Registry statusCompletedCombination Therapy Selection Trial in Amyotrophic Lateral Sclerosis
NCT00355576 · start 2006-07
Registered record
- Registry ID
- NCT00355576
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Celecoxib; Creatine; Minocycline
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2007-05
- Enrolment
- 86
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAmyotrophic Lateral SclerosisInterventionCelecoxib; Creatine; MinocyclinePhasePhase 2Registry statusCompletedS0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
NCT00088972 · start 2004-11
Registered record
- Registry ID
- NCT00088972
- Conditions
- Breast Cancer
- Interventions
- celecoxib; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2004-11
- Completion
- 2009-07
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventioncelecoxib; placeboPhasePhase 2Registry statusTerminatedPredicting Patients' Response to Spinal Manipulation
NCT00285649 · start 2004-07
Registered record
- Registry ID
- NCT00285649
- Conditions
- Low Back Pain
- Interventions
- HVLA-SM; LVVA-SM; Usual Medical Care
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2007-03
- Enrolment
- 192
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLow Back PainInterventionHVLA-SM; LVVA-SM; Usual Medical CarePhaseNot applicableRegistry statusCompletedEfficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk
NCT00194090 · start 2004-06
Registered record
- Registry ID
- NCT00194090
- Conditions
- Knee Osteoarthritis
- Interventions
- celecoxib
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2005-09-01
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKnee OsteoarthritisInterventioncelecoxibPhasePhase 4Registry statusCompleted